News

ORION is a randomized, double-blind, placebo-controlled study exploring the metabolic effects of cenicriviroc (CVC) in obese adults (BMI greater than or equal to 30 kg/m2) with prediabetes or

Following the issuance of the Company’s February 8, 2016, press release describing the partial clinical hold issued by the U.S. Food and Drug Administration (FDA) regarding those clinical

The study successfully met its pre-determined endpoints. Cancer progression clinical outcomes were significantly improved in the fexapotide treated patient groups. The clinical trial commenced in February 2012 at

The pay-for-performance agreements are expected to set pricing on certain drugs based on how they work for certain patients. In July 2015, the US Food and Drug Administration

The company said that it was informed by FDA that it will require another three months to complete its New Drug Application (NDA) review for eteplirsen. Sarepta received

Pharming entered into the original exclusive distribution agreement with Cytobioteck in May 2015 for the distribution of RUCONEST(R) in Colombia and Venezuela. Under the extended agreement, Cytobioteck will

The group comprising European experts is set to advice on any scientific and regulatory matters to conduct the research and development of medicines or vaccines against the mosquito-borne

CytRx has received the first $25 million of financing under the loan and security agreement. The proceeds will be used for pre-commercialization and manufacturing activities for aldoxorubicin, clinical

The benchtop GeneReader combines with other Qiagen NGS products to provide the first seamless, fully automated Sample to Insight workflow. Volpi optimized the GeneReader’s automated imaging module at